# Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05700084/  
OnCo record `nct05700084` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Capecitabine in advanced solid tumours, run by Beijing Biostar Pharmaceuticals Co., Ltd., active and no longer recruiting.

## Summary

Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05700084 by Beijing Biostar Pharmaceuticals Co., Ltd., with 84 participants enrolled, started 2023-06-09 and due to reach its primary completion in 2025-10-08. Interventions recorded: Utidelone Capsule (Part 1), Drug A Utidelone Capsule (Part 2: Group A-B), Drug A Utidelone Capsule (Part 2: Group B-A), Drug B Utidelone Injection (Part 2: Group A-B), Drug B Utidelone Injection (Part 2: Group B-A) and Capecitabine.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05700084
- Phase: 1/2
- Setting: Phase I-II Clinical Trial on Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors
- Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd.
- Enrolled: 84

## Sources

- ClinicalTrials.gov NCT05700084: https://clinicaltrials.gov/study/NCT05700084

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/)

---
JSON: https://onco.cc/api/v1/entities/nct05700084.json